IP Library › Granted Patent US 8,932,836
Granted Patent B2
US 8,932,836 · App. 13/817,295 · Granted Jan 13, 2015

Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine

Inventors: John Limanto (Metuchen, NJ); Gregory Beutner (Green Brook, NJ); Brendan Grau (Warrington, PA); Jacob Janey (New York, NY); Artis Klapars (Edison, NJ); Eric R. Ashley (Fanwood, NJ); Hallena R. Strotman (Monmouth Junction, NJ); Matthew D. Truppo (Ocean Township, NJ); Gregory Hughes (Scotch Plains, NJ); Fabien Cabirol (Dusseldorf, DE); Anupam Gohel (Singapore, SG); Steven J. Collier (Singapore, SG); Jack Liang (San Mateo, CA); Marissa Mock (Moorpark, CA); Emily Mundorff (Poughkeepsie, NY); Scott Novick (Palo Alto, CA); Derek Smith (Singapore, SG)
Assignee: Codexis, Inc.
C12P13/001C12N9/1096
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,932,836
App. No.
13/817,295
Granted
Jan 13, 2015
Kind
B2
Abstract

The disclosure provides transaminase polypeptides capable of converting the substrate, 2-(3,4-dimethoxyphenethoxy)cyclohexanone to the trans diastereomer product (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine in at least a 2:1 diastereomeric ratio relative to the cis diastereomer (1R,2S)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine. The disclosure also provides polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides in processes for preparing (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine and its analogs, which can product compounds can be further used to prepare the aminocyclohexylether compound, (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol, which is an ion channel blocker.

Claims (14)

1. An engineered transaminase comprising an amino acid sequence having at least 90% sequence identity to the reference polypeptide of SEQ ID NO: 6 and an amino acid residue difference as compared to SEQ ID NO: 6 at the positions X69V, X124I, and X136W.

2. The polypeptide of claim 1 in which the amino acid differences as compared to SEQ ID NO: 6 comprise X69V, X124I, and X136W.

3. The polypeptide of claim 2 in which the polypeptide amino acid sequence further comprises one or more amino acid residue differences as compared to SEQ ID NO: 6 selected from the following: X2K; X2Q; X2S; X4I; X4L; X5H; X5I; X5L; X5N; X5S; X5T; X5V; X7A; X8T; X9N; X9Q; X9S; X10V; X11K; X14R; X28P; X37R; X38G; X41F; X42A; X44Q; X44V; X52K; X54K; X54N; X54P; X54R; X55L; X56G; X56L; X56S; X58L; X94L; X99L; X108V; X126A; X126T; X135Q; X141L; X142R; X142T; X150A; X150F; X150N; X155A; X156A; X156F; X156G; X156S; X156T; X157L; X164A; X165N; X171A; X182T; X199F; X199R; X199Y; X209C; X209D; X209E; X210S; X213P; X215F; X215Y; X217S; X218M; X22I; X223I; X223L; X223M; X223N; X245S; X257F; X265T; X267V; X296S; and X328I.

4. The polypeptide of claim 1 in which the polypeptide is capable of converting a racemic mixture of compound (1) to compound (2a) in at least a 2:1 diastereomeric ratio relative to compound (2c) under suitable reaction conditions:

5. The polypeptide of claim 1 in which the polypeptide amino acid sequence comprises SEQ ID NO:206.

6. A polynucleotide encoding the polypeptide of claim 1 .

7. An expression vector comprising the polynucleotide of claim 6 .

8. A host cell comprising the polynucleotide of claim 6 .

9. A method for preparing a polypeptide comprising culturing a host cell of claim 8 and isolating the polypeptide from the cell.

10. A method for preparing (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine (compound (2a)),

comprising contacting (R)-2-(3,4-dimethoxyphenethoxy)cyclohexanone (compound (1a))

with a transaminase polypeptide of claim 1 in the presence of an amino donor under suitable reactions conditions.

11. The method of claim 10 , wherein the suitable reaction conditions comprise at least about 10 g/L compound (1a), at least about 1 g/L polypeptide, at least about 1 M isopropylamine, at least about 1 g/L pyridoxal 5′-phosphate, 0.2 M borate, at least about 20% (v/v) DMSO, pH 10.5, and 45° C.

12. The method of claim 10 , in which the method further comprises one or more steps selected from: extraction of compound (2a); isolation of compound (2a); forming a salt of compound (2a); purification of compound (2a); and crystallization of compound (2a).

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (3)
Provisional Application 61374079 · Aug 16, 2010
Provisional Application 61510256 · Jul 21, 2011
Related Publication 20130164794A1 · Jun 27, 2013